Comparing Sharps Technology (NASDAQ:STSS) & Haleon (NYSE:HLN)

Sharps Technology (NASDAQ:STSS) and Haleon (NYSE:HLN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Sharps Technology and Haleon’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-98.77%	-53.85%
Haleon	12.86%	17.65%	8.58%

Analyst Ratings

This is a breakdown of current ratings for Sharps Technology and Haleon, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	0	0	0	0	0.00
Haleon	0	5	4	2	2.73

Haleon has a consensus price target of $12.33, suggesting a potential upside of 25.59%. Given Haleon’s stronger consensus rating and higher probable upside, analysts plainly believe Haleon is more favorable than Sharps Technology.

Insider and Institutional Ownership

17.2% of Sharps Technology shares are held by institutional investors. Comparatively, 6.7% of Haleon shares are held by institutional investors. 1.5% of Sharps Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Sharps Technology and Haleon”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	N/A	N/A	-$9.30 million	($1,881.93)	0.00
Haleon	$14.35 billion	3.07	$1.84 billion	$0.39	25.16

Haleon has higher revenue and earnings than Sharps Technology. Sharps Technology is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Sharps Technology has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, Haleon has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Summary

Haleon beats Sharps Technology on 11 of the 14 factors compared between the two stocks.

About Sharps Technology

Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.